{
    "clinical_study": {
        "@rank": "16503", 
        "arm_group": {
            "arm_group_label": "EVG/COBI/FTC/TDF", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the\n      elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF)\n      single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV) treatment-naive\n      adolescents. Safety, tolerability, and efficacy will also be evaluated through Week 48.\n\n      A total of 50 adolescent participants (12 to < 18 years of age) will be enrolled to receive\n      EVG/COBI/FTC/TDF as follows:\n\n        -  Part A: Twelve to 16 eligible participants will be enrolled to evaluate steady-state\n           PK, and confirm the dose, with the intent to enroll at least 4 participants 12 to < 15\n           and at least 4 participants 15 to < 18 years of age.\n\n        -  Part B: Following confirmation of EVG exposure in at least 12 participants from Part A,\n           34 to 38 participants in addition to those enrolled in Part A will be enrolled to\n           evaluate the safety, tolerability and antiviral activity of EVG/COBI/FTC/TDF STR."
        }, 
        "brief_title": "Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acquired Immunodeficiency Syndrome", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  12 years to < 18 years of age at baseline\n\n          -  Able to give written assent prior to any screening evaluations\n\n          -  Parent or guardian able to give written informed consent prior to any screening\n             evaluations and willing to comply with study requirements\n\n          -  Plasma HIV-1 RNA levels of \u2265 1,000 copies/mL\n\n          -  CD4+ cell count > 100 cells/\u00b5L\n\n          -  Weight \u2265 35 kg (77 lbs)\n\n          -  Screening genotype report must show sensitivity to FTC and TDF\n\n          -  Able to swallow oral tablets\n\n          -  Adequate renal function\n\n          -  Clinically normal ECG\n\n          -  Documented screening for active pulmonary tuberculosis per local standard of care\n             within 6 months of a screening visit\n\n          -  Hepatic transaminases \u2264 5 x upper limit of normal\n\n          -  Total bilirubin \u2264 1.5 mg/dL, or normal direct bilirubin\n\n          -  Individuals with a positive Hepatitis B surface antigen screening test can\n             participate in the study, providing that alternate therapy (other than TDF) for\n             chronic Hepatitis B infection is available as a part of local standard of care\n\n          -  Adequate hematologic function\n\n          -  Negative serum pregnancy test for all females\n\n          -  Males and females of childbearing potential must agree to utilize highly effective\n             contraception methods while on study treatment or agree to abstain from heterosexual\n             intercourse throughout the study period and for 30 days following the last dose of\n             study drug\n\n          -  Males must agree to utilize a highly effective method of contraception during\n             heterosexual intercourse throughout the study period and for 30 days following\n             discontinuation of investigational medicinal product\n\n          -  Must be willing and able to comply with all study requirements\n\n          -  Life expectancy \u2265 1 year\n\n        Exclusion Criteria:\n\n          -  A new AIDS-defining condition diagnosed within the 30 days prior to screening\n\n          -  Prior treatment with any approved or investigational or experimental anti HIV-1 drug\n             for any length of time (other than that given for prevention of mother-to-child\n             transmission)\n\n          -  Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months\n             of the screening visit\n\n          -  Anticipated to require rifamycin treatment for mycobacterial infection while\n             participating in the study. Note: prophylactic Isoniazid (INH) therapy for latent\n             tuberculosis (TB) treatment is allowed.\n\n          -  Individuals experiencing decompensated cirrhosis\n\n          -  Pregnant or lactating females\n\n          -  Have any serious or active medical or psychiatric illness which would interfere with\n             treatment, assessment, or compliance with the protocol. This would include\n             uncontrolled renal, cardiac, hematological, hepatic, pulmonary, endocrine, central\n             nervous, gastrointestinal, vascular, metabolic, immunodeficiency disorders, active\n             infection, or malignancy that are clinically significant or requiring treatment\n             within 30 days prior to the study dosing.\n\n          -  Current alcohol or substance abuse that will potentially interfere with  compliance\n\n          -  Have history of significant drug sensitivity or drug allergy\n\n          -  Known hypersensitivity to the study drugs, the metabolites or formulation excipients\n\n          -  Have been treated with immunosuppressant therapies or chemotherapeutic agents within\n             3 months of study screening or expected to receive these agents during the study\n\n          -  A history of malignancy within the past 5 years or ongoing malignancy other than\n             cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous\n             squamous carcinoma\n\n          -  Have previously participated in an investigational trial involving administration of\n             any investigational agent within 30 days prior to the study dosing\n\n          -  Participation in any other clinical trial without prior approval from sponsor is\n             prohibited while participating in this trial\n\n          -  Receiving ongoing therapy with any disallowed medications, including drugs not to be\n             used with EVG, COBI, FTC, TDF or individuals with any known allergies to the\n             excipients of EVG/COBI/FTC/TDF STR tablets"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721109", 
            "org_study_id": "GS-US-236-0112"
        }, 
        "intervention": {
            "arm_group_label": "EVG/COBI/FTC/TDF", 
            "description": "Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EVG/COBI/FTC/TDF) single-tablet regiment (STR) administered orally once daily with food", 
            "intervention_name": "EVG/COBI/FTC/TDF", 
            "intervention_type": "Drug", 
            "other_name": "Stribild\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Adolescents", 
            "HIV-1", 
            "HIV", 
            "Treatment Naive"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "East Bay AIDS Center Medical Group"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Burack", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32209"
                    }, 
                    "name": "University of Florida, Jacksonville"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "University of South Florida - Department of Pediatrics"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10467"
                    }, 
                    "name": "Montefiore Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York University School of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "SUNY Upstate Medical University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "919-668-4851"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19134"
                    }, 
                    "name": "St. Christopher's Hospital for Children"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "St. Jude Children's Research Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara, Jalisco", 
                        "country": "Mexico", 
                        "zip": "44280"
                    }, 
                    "name": "Hospital Civil de Guadalajara"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "2112"
                    }, 
                    "name": "Rahima Moosa Mother and Child Hospital (Wits)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "state": "Kwazulu-Natal", 
                        "zip": "4001"
                    }, 
                    "name": "Dr Latiff Private Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7925"
                    }, 
                    "name": "Desmond Tutu HIV Research Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "South Africa", 
                        "zip": "3000"
                    }, 
                    "name": "Mpati Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gauteng", 
                        "country": "South Africa", 
                        "zip": "2013"
                    }, 
                    "name": "Perinatal HIV Research Unit"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2092"
                    }, 
                    "name": "Clinical HIV Research Unit"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stellenbosch", 
                        "country": "South Africa", 
                        "zip": "7602"
                    }, 
                    "name": "University of Stellenbosch"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Siriraj Hospital, Mahidol University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }, 
                    "name": "The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chonburi", 
                        "country": "Thailand", 
                        "zip": "20110"
                    }, 
                    "name": "Queen Savang Vadhana Memorial Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Khon Kaen", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }, 
                    "name": "Srinakarind Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Mexico", 
                "South Africa", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents", 
        "overall_contact": {
            "email": "skanda.goudar@gilead.com", 
            "last_name": "Skanda Goudar", 
            "phone": "650-524-4274"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Sean Bennett, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)", 
                "measure": "For Part A, plasma pharmacokinetics (PK) parameter of EVG as measured by AUCtau", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "SAEs and AEs will be summarized.", 
                "measure": "For Part B, incidence of treatment-emergent serious adverse events (SAEs) and all treatment-emergent adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 48 plus 30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721109"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval\nCmax is defined as the maximum observed concentration of drug in plasma\nAUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)", 
                "measure": "For Part A, PK parameter of EVG as measured by Ctau and Cmax and PK parameter of emtricitabine (FTC), tenofovir (TFV), and cobicistat (COBI) as measured by AUCtau, Cmax, and Ctau", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "measure": "For Part B, percentage of participants with plasma HIV-1 RNA < 50 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "For Part B, percentage of participants with plasma HIV-1 RNA < 400 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "For Part B, change from baseline in plasma log10 HIV-1 RNA (copies/mL)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "For Part B, change from baseline in CD4+ cell count (cells/\u03bcL) and percentage", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}